Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RVTY 
Revvity Inc. (RVTY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: RVTY (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $116.81
1 Year Target Price $116.81
| 10 | Strong Buy |
| 2 | Buy |
| 7 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.98% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.36B USD | Price to earnings Ratio 38.8 | 1Y Target Price 116.81 |
Price to earnings Ratio 38.8 | 1Y Target Price 116.81 | ||
Volume (30-day avg) 19 | Beta 0.92 | 52 Weeks Range 85.12 - 129.23 | Updated Date 08/29/2025 |
52 Weeks Range 85.12 - 129.23 | Updated Date 08/29/2025 | ||
Dividends yield (FY) 0.32% | Basic EPS (TTM) 2.3 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10.19% | Operating Margin (TTM) 14.31% |
Management Effectiveness
Return on Assets (TTM) 2.05% | Return on Equity (TTM) 3.61% |
Valuation
Trailing PE 38.8 | Forward PE 18.28 | Enterprise Value 12740166313 | Price to Sales(TTM) 3.7 |
Enterprise Value 12740166313 | Price to Sales(TTM) 3.7 | ||
Enterprise Value to Revenue 4.55 | Enterprise Value to EBITDA 15.5 | Shares Outstanding 116073000 | Shares Floating 108559202 |
Shares Outstanding 116073000 | Shares Floating 108559202 | ||
Percent Insiders 0.34 | Percent Institutions 100.24 |
Upturn AI SWOT
Revvity Inc.
Company Overview
History and Background
Revvity Inc. (formerly PerkinElmer) was founded in 1931. Originally known for analytical instruments, it has evolved into a life sciences and diagnostics company, focusing on healthcare advancements.
Core Business Areas
- Life Sciences: Provides solutions for drug discovery, research, and development, including reagents, instruments, and software.
- Diagnostics: Offers diagnostic testing solutions, focusing on newborn screening, reproductive health, and infectious disease detection.
Leadership and Structure
The leadership team includes Prahlad Singh (CEO). Revvity operates with a global organizational structure, organized around its Life Sciences and Diagnostics businesses.
Top Products and Market Share
Key Offerings
- Victor2D: A microplate reader used in drug discovery and research. Competitors include Thermo Fisher Scientific, Bio-Rad Laboratories. Market share data specific to this product is difficult to obtain.
- DELFIA Assays: A platform for immunoassays. Competitors include Roche, Abbott. Market share data specific to DELFIA is difficult to obtain.
- Newborn Screening Solutions: Products and services for newborn screening. Competitors include Roche, Agilent Technologies. Market share data specific to newborn screening solution is difficult to obtain.
Market Dynamics
Industry Overview
The life sciences and diagnostics industry is characterized by constant innovation, driven by advancements in genomics, proteomics, and personalized medicine. It is highly competitive.
Positioning
Revvity holds a strong position in the life sciences and diagnostics markets due to its broad product portfolio and established customer base. Its competitive advantage lies in its integrated solutions.
Total Addressable Market (TAM)
The total addressable market for life sciences and diagnostics is estimated to be in the hundreds of billions of dollars. Revvity is positioned to capture a portion of this market through its innovative technologies and solutions.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Diverse product portfolio
- Global presence
- Focus on innovation
Weaknesses
- Reliance on specific markets
- Exposure to economic cycles
- Integration challenges from acquisitions
Opportunities
- Expansion into emerging markets
- Partnerships with research institutions
- Development of personalized medicine solutions
- Growth in genetic testing
Threats
- Intense competition
- Regulatory changes
- Technological obsolescence
- Economic downturns
Competitors and Market Share
Key Competitors
- TMO
- DHR
- ABT
Competitive Landscape
Revvity competes in a highly competitive market. Its advantages include its broad product portfolio, but it faces challenges from larger companies with greater resources.
Major Acquisitions
BioLegend
- Year: 2021
- Acquisition Price (USD millions): 5250
- Strategic Rationale: Expanded Revvity's portfolio into high-growth areas of biologics, antibodies, and reagents for research and diagnostics.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are obtainable from Revvity's past financial reports.
Future Projections: Future projections are based on analyst estimates and company guidance, which change over time.
Recent Initiatives: Recent strategic initiatives include acquisitions, product launches, and partnerships.
Summary
Revvity is a solid player in the life sciences and diagnostics space with a diverse product portfolio. Its strategic acquisitions have strengthened its market position, but it faces intense competition. Revvity needs to focus on innovation and market expansion to sustain long-term growth and monitor changes to economic conditions.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Public Financial Reports
- Industry Analysis Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Revvity Inc.
Exchange NYSE | Headquaters Waltham, MA, United States | ||
IPO Launch date 1983-04-06 | CEO, President & Director Dr. Prahlad R. Singh Ph.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 11000 | Website https://www.revvity.com |
Full time employees 11000 | Website https://www.revvity.com | ||
Revvity, Inc. provides health sciences solutions, technologies, and services worldwide. The company's Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services. Its Diagnostics segment offers instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in oncology, screening newborns for rare genetic conditions, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific, BioQule, BoBs, chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPatternTM, Evolution Evoya, explorer, Fontus, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Omni Bead Ruptor, Omni Bead Ruptor Elite, Omni Tip, Pannoramic, Panthera Puncher, PG-Seq, PG-Find, PreNAT II, Prime, Protein Clear, ProteinEXact, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord, VICTOR2D, and Zephyr brands. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Mass
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.